Phase II-III trials of oral VP 16-213 (VP 16) were conducted in non-Hodgkin lymphoma (NHL) and small cell lung cancer (SCLC). Of 29 heavily pretreated patients (pts) with NHL treated VP 16 at a dose of 200 mg/d days 1-5 q 3w, there were 3 CRs and 6 PRs (CR + PR : 31%) lasting 16 (7-185) weeks. Of 19 pts with NHL in stages III-IV treated by a non-cross alternating regimen consisting of AVCP (ADM, VCR, CPM, PDN)/EMLP (VP 16, MTX, L-ASP PDN), there were 4 CRs (21%) and 14 PRs (74%) lasting a median duration of 4.5 months. A combination consisting of VCR. VP 16 and CPM (VEC) was administered to a total of 29 pts with SCLC. Nine out of 10 pts with LD and 10 out of 19 pts with ED were attained CR after 2 cycles of VEC and subsequent irradiation to primary tumor. A median survival time of CR (LD + ED) exceeded one year while that of PR was 7+ months. These results indicated that oral VP 16 has significant activity for NHL and SCLC and lack of cross resistance to conventional drugs used for NHL.
口服依托泊苷（VP 16）的II-III期试验在非霍奇金淋巴瘤（NHL）和小细胞肺癌（SCLC）中进行。在29例接受过大量预处理的NHL患者中，以200mg/d的剂量在第1 - 5天给予VP 16，每3周重复一次，有3例完全缓解（CR）和6例部分缓解（PR）（CR + PR：31%），持续时间为16（7 - 185）周。在19例III-IV期NHL患者中，采用由AVCP（阿霉素、长春新碱、环磷酰胺、泼尼松）/EMLP（依托泊苷、甲氨蝶呤、左旋门冬酰胺酶、泼尼松）组成的非交叉交替方案进行治疗，有4例CR（21%）和14例PR（74%），中位持续时间为4.5个月。将由长春新碱、依托泊苷和环磷酰胺（VEC）组成的联合方案应用于总共29例SCLC患者。在10例局限性疾病（LD）患者中有9例以及19例广泛性疾病（ED）患者中有10例在接受2个周期的VEC治疗及随后对原发肿瘤进行照射后达到CR。CR（LD + ED）患者的中位生存时间超过1年，而PR患者的中位生存时间为7 + 个月。这些结果表明口服依托泊苷对NHL和SCLC具有显著活性，并且对用于NHL的传统药物缺乏交叉耐药性。
Zotero 插件